Cognition Therapeutics, Inc. (CGTX) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 Purchase, NY, 美国. 现任CEO为 Lisa Ricciardi.
CGTX 拥有 IPO日期为 2021-10-08, 25 名全职员工, 在 NASDAQ Global Market, 市值为 $71.77M.
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
